Your browser doesn't support javascript.
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Ogbe, Ane; Pace, Matthew; Bittaye, Mustapha; Tipoe, Timothy; Adele, Sandra; Alagaratnam, Jasmini; Aley, Parvinder K; Ansari, M Azim; Bara, Anna; Broadhead, Samantha; Brown, Anthony; Brown, Helen; Cappuccini, Federica; Cinardo, Paola; Dejnirattisai, Wanwisa; Ewer, Katie J; Fok, Henry; Folegatti, Pedro M; Fowler, Jamie; Godfrey, Leila; Goodman, Anna L; Jackson, Bethany; Jenkin, Daniel; Jones, Mathew; Longet, Stephanie; Makinson, Rebecca A; Marchevsky, Natalie G; Mathew, Moncy; Mazzella, Andrea; Mujadidi, Yama F; Parolini, Lucia; Petersen, Claire; Plested, Emma; Pollock, Katrina M; Rajeswaran, Thurkka; Ramasamy, Maheshi N; Rhead, Sarah; Robinson, Hannah; Robinson, Nicola; Sanders, Helen; Serrano, Sonia; Tipton, Tom; Waters, Anele; Zacharopoulou, Panagiota; Barnes, Eleanor; Dunachie, Susanna; Goulder, Philip; Klenerman, Paul; Screaton, Gavin R; Winston, Alan.
  • Ogbe A; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Pace M; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Bittaye M; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Tipoe T; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Adele S; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Alagaratnam J; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.
  • Aley PK; Department of HIV Medicine, St. Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Ansari MA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Bara A; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Broadhead S; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, United Kingdom.
  • Brown A; NIHR Guy's and St Thomas' Biomedical Research Centre, London, United Kingdom.
  • Brown H; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Cappuccini F; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Cinardo P; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Dejnirattisai W; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guy's and St Thomas' NHS Trust, London, United Kingdom.
  • Ewer KJ; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Fok H; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Folegatti PM; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guy's and St Thomas' NHS Trust, London, United Kingdom.
  • Fowler J; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Godfrey L; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Goodman AL; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Jackson B; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guy's and St Thomas' NHS Trust, London, United Kingdom.
  • Jenkin D; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guy's and St Thomas' NHS Trust, London, United Kingdom.
  • Jones M; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Longet S; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Makinson RA; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Marchevsky NG; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Mathew M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Mazzella A; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guy's and St Thomas' NHS Trust, London, United Kingdom.
  • Mujadidi YF; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guy's and St Thomas' NHS Trust, London, United Kingdom.
  • Parolini L; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Petersen C; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Plested E; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.
  • Pollock KM; Department of HIV Medicine, St. Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Rajeswaran T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Ramasamy MN; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, United Kingdom.
  • Rhead S; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guy's and St Thomas' NHS Trust, London, United Kingdom.
  • Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Robinson N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Sanders H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Serrano S; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Tipton T; NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
  • Waters A; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Zacharopoulou P; NIHR Guy's and St Thomas' Biomedical Research Centre, London, United Kingdom.
  • Barnes E; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Dunachie S; Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guy's and St Thomas' NHS Trust, London, United Kingdom.
  • Goulder P; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Klenerman P; Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine, and.
  • Screaton GR; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Winston A; NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
JCI Insight ; 7(7)2022 04 08.
Article in English | MEDLINE | ID: covidwho-1702851
ABSTRACT
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/µL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans / Male Language: English Year: 2022 Document Type: Article

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans / Male Language: English Year: 2022 Document Type: Article